<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="133294">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01366534</url>
  </required_header>
  <id_info>
    <org_study_id>114460</org_study_id>
    <nct_id>NCT01366534</nct_id>
  </id_info>
  <brief_title>Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-na誰ve Adults</brief_title>
  <official_title>Safety, Immunogenicity and Efficacy Against Malaria in the Sporozoite Challenge Model of One Dose of Ad35.CS.01 Malaria Vaccine Followed by Two Doses of Malaria 257049 Vaccine in Healthy Malaria-na誰ve Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The PATH Malaria Vaccine Initiative (MVI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will evaluate whether administration of two investigational malaria vaccines
      (257049 and Ad35.CS.01 vaccines) combined in one immunization schedule increases protection
      against malaria infection as compared to protection induced by the 257049 vaccine alone. The
      study will also evaluate the safety and the immune response to the new combination of the
      two experimental malaria vaccines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 168 healthy, malaria-na誰ve volunteers aged 18 - 50 years, divided into 2
      groups (84 in each group), will receive either one dose of Ad35.CS.01 followed by two doses
      of 257049 at monthly intervals or 3 doses of 257049 vaccine at monthly intervals. Of these,
      a maximum of 138 vaccinated volunteers will be challenged with P. falciparum infected
      mosquitoes. The challenge will occur 2 weeks following the third immunization. A group of up
      to 18 infectivity controls will begin participation in the study at the challenge stage.
      These controls receive no vaccine and are enrolled for malaria-challenge only in order to
      provide comparison group for vaccinated individuals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of P. falciparum parasitemia, defined by a positive blood slide</measure>
    <time_frame>From baseline (day of challenge) up to 159 days post-challenge</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of each solicited adverse event</measure>
    <time_frame>After each vaccine administration, over a 7-day follow-up period (day of vaccination and 6 subsequent days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of unsolicited adverse events after vaccination</measure>
    <time_frame>After each vaccine administration, over a 30-day follow-up period (day of vaccination and 29 subsequent days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of unsolicited adverse events after challenge</measure>
    <time_frame>After challenge, over a 30-day follow-up period (day of challenge and 29 subsequent days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events (SAEs) within 30 days after each vaccination</measure>
    <time_frame>After each vaccine administration, over a 30-day follow-up period (day of vaccination and 29 subsequent days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of SAEs during the whole study period</measure>
    <time_frame>From the time of first vaccination up to 236 days post-dose 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to P. falciparum parasitemia, defined by a positive blood slide</measure>
    <time_frame>From baseline (day of challenge) up to 159 days post-challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti- circumsporozoite protein (anti-CS) (repeat) and anti-hepatitis B (anti-HBs) antibody titres</measure>
    <time_frame>28 days post-dose 1 (Day 28), 28 days post-dose 2 (Day 56), 21 days post-dose 3 (Day 77 = Day of challenge), 28 days post-challenge (Day 105), 63 days post-challenge (Day 140), 159 days post-challenge (Day 236)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-adenovirus type 35 (anti-Ad35) neutralizing antibody titers</measure>
    <time_frame>28 days post-dose 1 (Day 28), 28 days post-dose 2 (Day 56), 21 days post-dose 3 (Day 77 = Day of challenge), 28 days post-challenge (Day 105), 63 days post-challenge (Day 140), 159 days post-challenge (Day 236)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of CS (total CS or repeat)-specific T cells</measure>
    <time_frame>14 days post-dose 1 (Day 14), 14 days post-dose 2 (Day 42), 21 days post-dose 3 (Day 77 = Day of challenge), 28 days post-challenge (Day 105), 63 days post-challenge (Day 140), 159 days post-challenge (Day 236)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of HBs-specific T cells</measure>
    <time_frame>14 days post-dose 2 (Day 42), 21 days post-dose 3 (Day 77 = Day of challenge), 28 days post-challenge (Day 105), 63 days post-challenge (Day 140), 159 days post-challenge (Day 236)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers enrolled to this group will receive 1 dose of Ad35.CS.01 vaccine followed by 2 doses of the malaria 257049 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers enrolled to this group will receive 3 doses of the investigational malaria 257049 vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)</intervention_name>
    <description>One dose will be administered intramuscularly at Study Day 0.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' malaria vaccine 257049 (2 doses)</intervention_name>
    <description>Two doses will be administered intramuscularly at monthly intervals</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' malaria vaccine 257049 (3 doses)</intervention_name>
    <description>Three doses will be administered intramuscularly at monthly intervals</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol.

          -  A male or non-pregnant female 18 to 50 years of age at the time of first vaccination.

          -  Written informed consent obtained from the subject before screening procedures.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Available to participate for the duration of the study.

          -  Female subjects of non-childbearing potential.

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

               -  has practiced adequate Food and Drug Administration (FDA)-approved contraception
                  for 30 days prior to vaccination, and

               -  has a negative pregnancy test on the day of vaccination, and

               -  has agreed to continue adequate FDA-approved contraception during the entire
                  treatment period and for 2 months after completion of the vaccination series
                  and/or malaria challenge.

          -  Pass a comprehension assessment test.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product within 30 days preceding the
             first dose of study vaccine, or planned use of any investigational or non-registered
             product other than the study vaccines during the study period.

          -  Planned administration/ administration of a vaccine not foreseen by the study
             protocol within 7 days of the first dose of vaccines.

          -  Prior receipt of an investigational malaria or adenovirus vaccine.

          -  Chronic use of antibiotics with antimalarial effects.

          -  History of malaria chemoprophylaxis within 60 days prior to vaccination.

          -  Any history of malaria.

          -  Planned travel to malaria endemic areas during the study period.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine(s) including latex.

          -  History of allergic disease or reactions likely to be exacerbated by chloroquine.

          -  History of psoriasis and porphyria, which may be exacerbated after chloroquine
             treatment.

          -  Current use of medications known to cause drug reactions to chloroquine, such as
             antacids and kaolin.

          -  Any history of anaphylaxis in reaction to any previous vaccination.

          -  History of severe reactions to mosquito bites.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Chronic administration of immunosuppressants or other immune modifying drugs within
             six months prior to first vaccine dose.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             immunodeficiency virus (HIV) infection.

          -  Family history of congenital or hereditary immunodeficiency.

          -  History of splenectomy.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurological disorders or seizures.

          -  Acute disease and/or fever at the time of enrollment.

          -  Acute disease is defined as the presence of a moderate or severe illness with or
             without fever. Subjects with a minor illness without fever may be enrolled at the
             discretion of the investigator.

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination or laboratory screening
             tests.

          -  Any abnormal baseline laboratory screening tests.

          -  Evidence of increased cardiovascular disease risk, &quot;moderate&quot; or &quot;high&quot;, according to
             the NHANES I criteria.

          -  An abnormal baseline screening electrocardiogram (EKG).

          -  Hepatomegaly, right upper quadrant abdominal pain or tenderness.

          -  Personal history of autoimmune disease.

          -  Seropositive for hepatitis B surface antigen or Hepatitis C virus (antibodies to
             HCV).

          -  Pregnant or lactating female.

          -  Female who intends to become pregnant during the study or planning to discontinue
             contraceptive measures.

          -  Suspected or known current alcohol abuse.

          -  Chronic or active intravenous drug use.

          -  History of blood donation within 56 days preceding enrolment.

          -  Any other significant finding that in the opinion of the investigator would increase
             the risk of having an adverse outcome from participating in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Silver Springs</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Ockenhouse et al. Phase 1/2a vaccine trial with sporozoite challenge of Ad35.CS.01 - RTS,S/AS01 prime boost second generation malaria vaccine candidate administered in healthy malaria-na誰ve adults. Abstract presented at the 61st Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), Atlanta, GA, 11-15 November 2012.</citation>
  </reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>June 2, 2011</firstreceived_date>
  <firstreceived_results_disposition_date>November 16, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Phase 1/2</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>Malaria</keyword>
  <keyword>efficacy</keyword>
  <keyword>sporozoite challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114460</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114460</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114460</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114460</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114460</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114460</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
